About Aspect Biosystems
Aspect Biosystems is a company based in Vancouver (Canada) founded in 2013 by Simon Beyer, Tamer Mohamed, Sam Wadsworth, and Konrad Walus. Aspect Biosystems has raised $138.68 million across 5 funding rounds from investors including Novo Nordisk, Innovate BC and Canadian Space Agency. Aspect Biosystems offers products and services including Bioprinting Technology Platform. Aspect Biosystems operates in a competitive market with competitors including Nuclera Nucleics, CELLINK, Collplant, ROKIT Healthcare and Triastek, among others.
- Headquarter Vancouver, Canada
- Founders Simon Beyer, Tamer Mohamed, Sam Wadsworth, Konrad Walus
-
Sectors
Technology
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aspect Biosystems Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$138.68 M (USD)
in 5 rounds
-
Latest Funding Round
$115 M (USD), Series B
Jan 08, 2025
-
Investors
Novo Nordisk
& 11 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aspect Biosystems
Aspect Biosystems offers a comprehensive portfolio of products and services, including Bioprinting Technology Platform.
AI-powered system for creating implantable tissues to treat diseases.
People of Aspect Biosystems
Unlock access to complete
Unlock access to complete
Funding Insights of Aspect Biosystems
Aspect Biosystems has successfully raised a total of $138.68M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $115 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aspect Biosystems
Aspect Biosystems has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Novo Nordisk, Innovate BC and Canadian Space Agency.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Dimension is focused on investments at the intersection of technology and life sciences.
|
Locked | Locked | Locked | |
|
Early-stage sector agnostic VC firm investing primarily in the US and Canada
|
Locked | Locked | Locked | |
|
Companies developing T1D products are funded through venture philanthropy.
|
Locked | Locked | Locked |
Investor details for Aspect Biosystems
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aspect Biosystems
Investment portfolio details for Aspect Biosystems
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aspect Biosystems
Detailed financials for Aspect Biosystems
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aspect Biosystems Comparisons
Peer comparison for Aspect Biosystems
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aspect Biosystems
Aspect Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuclera Nucleics, CELLINK, Collplant, ROKIT Healthcare and Triastek, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Desktop bioprinter for genes and proteins production is developed.
|
|
| Locked | Locked | Locked |
3D bioprinters and bioinks are developed for research applications.
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
|
| Locked | Locked | Locked |
4D bio-printer solutions for tissue regeneration are provided.
|
|
| Locked | Locked | Locked |
Provider of 3D printing pharmaceutical technology platform for drug design
|
Detailed competitors of Aspect Biosystems
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aspect Biosystems
Complete news archive for Aspect Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aspect Biosystems
Aspect Biosystems was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Aspect Biosystems is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Tamer Mohamed is the current CEO of Aspect Biosystems. They have also founded this company.
Aspect Biosystems is a funded company, having raised a total of $138.68M across 5 funding rounds to date.
Aspect Biosystems was founded in 2013 in Vancouver, Canada. Bioprinting technology and tissue therapeutics are developed within the regenerative medicine sector. The platform is integrated with computational design, therapeutic cells, and biomaterials to produce implantable tissues. These tissues are designed to replace, repair, or supplement biological functions, particularly for metabolic and endocrine diseases. Collaborations with other organizations are maintained to advance operations.
Aspect Biosystems's top competitors include Nuclera Nucleics, Allevi and Collplant.
Aspect Biosystems offers Bioprinting Technology Platform.
Aspect Biosystems has 12 investors. Key investors include Novo Nordisk, Innovate BC, Canadian Space Agency, Dimension, and Pallasite Ventures.